Vol. 3, No. 6 Monday: November 15, 2004 e-street journal
Unsubscribe Company Profiles; Acorns to Oaks
education
editorials
21st Century Medicine: Genetic therapy promises dramatic change from treating symptoms to eliminating the disease
"Things are only impossible until they're not."
-- Jean-Luc, Star Trek, The Next Generation
"Our increasing understanding of the mechanisms of conversion of the genetic code into function indicates that gene based therapy will become a mainstay of disease control in the 21st century." O. Michael Colvin, Duke University Medical center.
"Every person", says Dari Shalon, Director of the Center of Genomics Research at Harvard University, "has 100,000 genes but some will malfunction, creating diseases. Through gene therapy," Professor Shalon continues. "a gene can be altered and a disease or condition can be treated."
One emerging company, CytoGenix,Inc.(CYGX) promises to have an impressive impact on medicine in the 21st century. Founded in 1995, the Company owns U.S. and foreign patents for a gene regulation technology that has been shown to be effective in targeting and reducing gene expression and providing potentially therapeutic agents for the treatment of human and animal diseases.
CytoGenix has developed Antisense and DNA enzymatic systems to "turn off" proteins involved in Herpes Simplex, Inflammation and Alopecia (pattern baldness). Anecdotal results have shown: Prevention of herpes lesions. Decrease in frequency of herpetic lesions. Growth of hair on male scalps which had been previously bald. Decrease in size and severity of Psoriasis lesions.
"Genetic Activity is at the root of virtually all disease states." says renowned researcher and Vice President of CYGX, Dr Yin Chen. "Genetically based therapies," Dr. Chen continues, "have the potential to shift the emphasis of healthcare from palliative to prevention; that is, from simply treating symptoms to actually eliminating disease."
The magic bullet. Modern medicine has found ways to send signals to the body's DNA to alter a structure that is either malfunctioning or failing to function at maximum potential. Hundreds of these so-called magic bullets have been designed; some by other companies. The problem, to date, has been finding a way to get the bullet quickly, efficiently and in sufficient quantity to the gene in need of change. CytoGenix has solved this important problem with their patented, proprietary technology. It is this technology that may enable CYGX to capture a significant share of a massive market in the USA and the world.
CYGX has management team uniquely equipped to capture a significant share of this vast market. Leading the team, CEO Malcolm Skolnick, a registered patent attorney and a PhD in physics, offers unique skills and experience as a researcher conducting clinical trials, as a patented inventor, as a former chairman of a NIH study section and as licensing officer for the University of Texas Health Science Center at Houston. On the team, in addition to other outstanding researchers and financial experts is Dr.Yin Chen who is one of the co-inventors of CytoGenix's proprietary ssDNA system technology. A scientific advisory board assists the management team.
Scientific Advisory Board. The Scientific Advisory Board reviews and critiques data when the company seeks scrutiny and verification of pertinent scientific/technical matters. This prestigious board includes respected academic physicians, and internationally recognized researchers in some of America's leading universities. The Company enters the market with confidence.
"We know our ssDNA expression system works." said CEO Skolnick," The proof of concept phase is over. We are now ready to develop our broad-based technology into important therapeutics to eliminate or ameliorate specific disorders."
Commercial opportunities for gene therapy. CEO Skolnick, points out some of the many areas where gene therapy can make a major contribution: Therapeutics. the extreme specificity of gene therapy offers real therapeutic promise for cancer and viral infections .Anti-viral drugs and vaccines are estimated to be about a third of the approximately $7 billion spent worldwide on anti-infectives last year. For aids alone the statistics are staggering. The Centers for Disease Control estimate that in the United States 1 to 1.5 million people are infected with HIV. Agriculture The use of gene therapy to develop agricultural animals or crops that are resistant to viruses or other diseases has considerable commercial significance. In the United States, for example, it is estimated that viruses are responsible for the loss of $1.5 to $2 billion in crop value each year. Bioprocessing industry The cost of failed drug discovery is the biggest drain on pharmaceutical profits. A recent industry study estimates the cost of developing a new drug at $880 million, and 75% of this cost is due to failed drugs. CytoGenix anticipates that pharmaceutical companies will welcome the fast turnaround Target Validation service CYGX can provide. The total Target Validation market is now worth $200-$500 million and will grow at the rate of 30% annually the next ten years.
As part of the important Drug Target Validation Service, CYGX is the sole pioneer in developing novel business structures to effectively combine leading edge biotechnology with traditional pharmacology through PharmaGenix, LLC, a joint enterprise with the Professional Compounding Centers of America, and their nearly 3,000 member compounding pharmacists.
It may well be that many previously incurable diseases will be cured through the gene therapy. CytoGenix, Inc. will play a vital role in this effort because of the insight of the company's leadership. CEO Malcolm Skolnick understands and agrees with an observation made long ago:
"It's not what you look at that matters, It's what you see."
-- Henry David Thoreau
Perhaps when you look at CYGX you will see
that it has an important place in your portfolio
www.cytogenix.com
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Statements in these newsletters regarding any company's reported business that are not historical facts are "forward-looking statements" that involve risk and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the company's Annual Report or Form 10k for the most recently ended fiscal year.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED WRITTEN CONSENT OF THE EDITORS OF THE E Street Journal.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at www.sec.gov and or the National Association of Securities Dealers (NASDAQ) at www.nasd.com
Vol. 3, No. 6 Monday: November 15, 2004 e-street journal
Unsubscribe Company Profiles; Acorns to Oaks
education
editorials
21st Century Medicine: Genetic therapy promises dramatic change from treating symptoms to eliminating the disease
"Things are only impossible until they're not."
-- Jean-Luc, Star Trek, The Next Generation
"Our increasing understanding of the mechanisms of conversion of the genetic code into function indicates that gene based therapy will become a mainstay of disease control in the 21st century." O. Michael Colvin, Duke University Medical center.
"Every person", says Dari Shalon, Director of the Center of Genomics Research at Harvard University, "has 100,000 genes but some will malfunction, creating diseases. Through gene therapy," Professor Shalon continues. "a gene can be altered and a disease or condition can be treated."
One emerging company, CytoGenix,Inc.(CYGX) promises to have an impressive impact on medicine in the 21st century. Founded in 1995, the Company owns U.S. and foreign patents for a gene regulation technology that has been shown to be effective in targeting and reducing gene expression and providing potentially therapeutic agents for the treatment of human and animal diseases.
CytoGenix has developed Antisense and DNA enzymatic systems to "turn off" proteins involved in Herpes Simplex, Inflammation and Alopecia (pattern baldness). Anecdotal results have shown: Prevention of herpes lesions. Decrease in frequency of herpetic lesions. Growth of hair on male scalps which had been previously bald. Decrease in size and severity of Psoriasis lesions.
"Genetic Activity is at the root of virtually all disease states." says renowned researcher and Vice President of CYGX, Dr Yin Chen. "Genetically based therapies," Dr. Chen continues, "have the potential to shift the emphasis of healthcare from palliative to prevention; that is, from simply treating symptoms to actually eliminating disease."
The magic bullet. Modern medicine has found ways to send signals to the body's DNA to alter a structure that is either malfunctioning or failing to function at maximum potential. Hundreds of these so-called magic bullets have been designed; some by other companies. The problem, to date, has been finding a way to get the bullet quickly, efficiently and in sufficient quantity to the gene in need of change. CytoGenix has solved this important problem with their patented, proprietary technology. It is this technology that may enable CYGX to capture a significant share of a massive market in the USA and the world.
CYGX has management team uniquely equipped to capture a significant share of this vast market. Leading the team, CEO Malcolm Skolnick, a registered patent attorney and a PhD in physics, offers unique skills and experience as a researcher conducting clinical trials, as a patented inventor, as a former chairman of a NIH study section and as licensing officer for the University of Texas Health Science Center at Houston. On the team, in addition to other outstanding researchers and financial experts is Dr.Yin Chen who is one of the co-inventors of CytoGenix's proprietary ssDNA system technology. A scientific advisory board assists the management team.
Scientific Advisory Board. The Scientific Advisory Board reviews and critiques data when the company seeks scrutiny and verification of pertinent scientific/technical matters. This prestigious board includes respected academic physicians, and internationally recognized researchers in some of America's leading universities. The Company enters the market with confidence.
"We know our ssDNA expression system works." said CEO Skolnick," The proof of concept phase is over. We are now ready to develop our broad-based technology into important therapeutics to eliminate or ameliorate specific disorders."
Commercial opportunities for gene therapy. CEO Skolnick, points out some of the many areas where gene therapy can make a major contribution: Therapeutics. the extreme specificity of gene therapy offers real therapeutic promise for cancer and viral infections .Anti-viral drugs and vaccines are estimated to be about a third of the approximately $7 billion spent worldwide on anti-infectives last year. For aids alone the statistics are staggering. The Centers for Disease Control estimate that in the United States 1 to 1.5 million people are infected with HIV. Agriculture The use of gene therapy to develop agricultural animals or crops that are resistant to viruses or other diseases has considerable commercial significance. In the United States, for example, it is estimated that viruses are responsible for the loss of $1.5 to $2 billion in crop value each year. Bioprocessing industry The cost of failed drug discovery is the biggest drain on pharmaceutical profits. A recent industry study estimates the cost of developing a new drug at $880 million, and 75% of this cost is due to failed drugs. CytoGenix anticipates that pharmaceutical companies will welcome the fast turnaround Target Validation service CYGX can provide. The total Target Validation market is now worth $200-$500 million and will grow at the rate of 30% annually the next ten years.
As part of the important Drug Target Validation Service, CYGX is the sole pioneer in developing novel business structures to effectively combine leading edge biotechnology with traditional pharmacology through PharmaGenix, LLC, a joint enterprise with the Professional Compounding Centers of America, and their nearly 3,000 member compounding pharmacists.
It may well be that many previously incurable diseases will be cured through the gene therapy. CytoGenix, Inc. will play a vital role in this effort because of the insight of the company's leadership. CEO Malcolm Skolnick understands and agrees with an observation made long ago:
"It's not what you look at that matters, It's what you see."
-- Henry David Thoreau
Perhaps when you look at CYGX you will see
that it has an important place in your portfolio
www.cytogenix.com
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Statements in these newsletters regarding any company's reported business that are not historical facts are "forward-looking statements" that involve risk and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the company's Annual Report or Form 10k for the most recently ended fiscal year.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED WRITTEN CONSENT OF THE EDITORS OF THE E Street Journal.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at www.sec.gov and or the National Association of Securities Dealers (NASDAQ) at www.nasd.com
